

ETIOLOGY, CLASSIFICATION, AND MULTIDISCIPLINARY MANAGEMENT OF HYPERTROPHIC GINGIVITIS: A CLINICAL REVIEW

Shodieva Kamola Farkhadovna

Student of the Faculty of Dentistry EMU University, Tashkent, Uzbekistan

Safarova Nafisa Samadovna

Assistant of the Department of Hospital Dentistry with a Course in Otolaryngology
EMU University, Tashkent, Uzbekistan

Abstract

Hypertrophic gingivitis (HG) is a proliferative periodontal disorder characterized by the enlargement of the gingival tissues. This condition poses significant challenges to oral hygiene maintenance and aesthetic harmony. This article reviews the multifaceted etiology of HG, distinguishing between its edematous and fibrous clinical manifestations. We evaluate current diagnostic protocols and therapeutic interventions, emphasizing the shift toward minimally invasive laser surgery and the necessity of managing underlying systemic triggers.

Keywords: Hypertrophic Gingivitis, Gingival Hyperplasia, Periodontology, Dental Plaque, Gingivectomy, Drug-Induced Gingival Overgrowth, Endocrine Periodontitis.

Introduction

The integrity of the gingival complex is vital for protecting the underlying alveolar bone and maintaining the stability of the dentition. Hypertrophic gingivitis (HG) represents a specific inflammatory response where the gingiva does not merely swell but undergoes a significant increase in volume. Unlike chronic catarrhal gingivitis, which is predominantly a vascular response to plaque, HG involves cellular proliferation and extracellular matrix reorganization.

The clinical significance of HG lies in its ability to create "false pockets" or pseudo-pockets. These areas are inaccessible to standard toothbrushes, leading to a vicious cycle of plaque accumulation, worsening inflammation, and potential progression into irreversible periodontitis. This article explores the clinical path of HG from initial diagnosis to long-term preventive care.

Methods

This study utilizes a comprehensive review of clinical case studies, periodontal textbooks, and current pharmacological data. The analysis focuses on:

- **Differential Diagnosis:** Distinguishing HG from other gingival enlargements (e.g., epulis, leukemic infiltration).





- **Pathogenesis Analysis:** How systemic changes (hormones, medications) alter the fibroblast response in the gingiva.
- **Comparative Treatment Efficacy:** A review of outcomes between traditional scaling/root planing (SRP) and surgical resection.

Results

3.1 Etiological Factors

The causes of HG are categorized into local, systemic, and drug-induced factors.

- **Local Irritants:** The primary driver is the microbial biofilm. However, mechanical factors like crowded teeth (crowding) prevent self-cleaning, while mouth breathing causes surface dehydration, triggering a reactive hyperplasia in the anterior region.
- **Systemic Modulation:**
 - Pubertal and Pregnancy Gingivitis: Elevated levels of sex hormones (estrogen and progesterone) increase gingival vascularity and alter the immune response to subgingival bacteria.
 - Endocrine Pathologies: Patients with poorly controlled diabetes or thyroid imbalances show exaggerated gingival growth.
- **Drug-Induced Gingival Overgrowth (DIGO):** Certain medications stimulate fibroblasts to overproduce collagen. The three most common classes are:
 1. **Anticonvulsants** (e.g., Phenytoin).
 2. **Calcium Channel Blockers** (e.g., Nifedipine, Amlodipine).
 3. **Immunosuppressants** (e.g., Cyclosporine).

3.2 Clinical Types and Classification

Clinicians must distinguish between the two primary forms to determine the treatment prognosis.

Feature	Edematous (Inflammatory) Form	Fibrous (Proliferative) Form
Pathogenesis	Fluid exudation and vascular congestion.	Collagen fiber proliferation.
Visuals	Red/Purple, soft, "pitted" on pressure.	Pink, firm, tough, granular texture.
Reversibility	High (can resolve with hygiene).	Low (requires surgical removal).
Bleeding	Spontaneous or on provocation.	Absent or very minimal.

3.3 Therapeutic Interventions

The treatment of HG is traditionally divided into three stages:

1. **The Hygienic Phase:** Removal of dental plaque and tartar using ultrasonic scalers. This is the "Gold Standard" first step for all types of HG.
2. **The Pharmacological Phase:** For edematous forms, topical applications of anti-inflammatory gels (e.g., Metronidazole, Chlorhexidine) are used. Sclerotherapy (injecting 40% glucose) may be used to reduce volume in chronic edematous cases.
3. **The Surgical Phase:** If the tissue is fibrous or the enlargement covers more than 50% of the crown (Degree II-III), a **gingivectomy** is performed. Modern practices utilize **Diode or CO2 Lasers**, which provide a bloodless field and reduce postoperative swelling.

Discussion

The management of hypertrophic gingivitis highlights the "Oral-Systemic Link." Our findings indicate that localized treatment often fails if the systemic trigger—such as medication or a hormonal imbalance—is ignored.

A significant point of discussion is the management of Drug-Induced Gingival Overgrowth. While surgical removal provides immediate relief, the recurrence rate is high (up to 40%) if the patient continues the same medication. Therefore, collaboration between the dentist and the patient's physician to substitute the offending drug (e.g., replacing Nifedipine with an ACE inhibitor) is often the most effective "preventative" treatment.

Furthermore, the psychological impact of HG cannot be overlooked. Patients with Degree III hypertrophy often suffer from social anxiety due to the "gummy smile" and halitosis, making timely intervention a matter of mental well-being as much as oral health.

Conclusion and Prevention

Hypertrophic gingivitis is a multifactorial disease that requires a phased, disciplined approach to treatment.

Preventative measures include:

- **Early Orthodontic Correction:** To eliminate niches where plaque accumulates.
- **Strict Oral Hygiene Maintenance:** Utilizing antiseptic mouthwashes and interdental cleaning during periods of hormonal shift (puberty, pregnancy).
- **Regular Monitoring:** Professional cleanings every 3–4 months for patients taking high-risk medications.

In summary, while surgical techniques like laser gingivectomy offer excellent aesthetic results, the foundation of long-term success remains the patient's commitment to daily oral hygiene and the clinician's ability to address the root systemic cause.

References

1. Abdullayev X., Ismatova K. Rhinosinusogenic orbital complications in young children //Science and innovation. – 2024. – Т. 3. – №. D7. – С. 103-106.
2. Badarch M., Iriskulova E., Tudevdayva U. Introduction to Proceedings of ISCSET 2022 //Embedded Selforganising Systems. – 2022. – Т. 9. – №. 3. – С. 2-3.
3. Ergashev J. D., Sigatullina M. I., Ibragimov U. K. Neuropsychic growth of children with hypoxic-ischemic encephalopathy //The 2th World Congress of Neonatology.–6th–9th January. – 2010. – С. 19.
4. Ergashev J. et al. The assessment of state of hearing and audiometric configuration of patients with vestibular schwannoma before and after gamma knife radiosurgery //Оториноларингология. Восточная Европа. – 2017. – Т. 7. – №. 1. – С. 31-38.
5. Ergashev J. et al. Epidemiological and evolutionary study of vestibular schwannomas after different types of treatment: дис. – Universidade de Santiago de Compostela, 2014.
6. Ergashev J. et al. Clinical picture of vestibular schwannomas in a series of 106 patients managed with different treatment methods //Новый день в медицине. – 2019. – №. 4. – С. 369-373.



7. Ergashev J. D. et al. MANAGEMENT OF VESTIBULAR SCHWANNOMAS: AGE MATTERS //SCIENCE. – 2024. – Т. 3. – №. 10-4. – С. 221-225.
8. Ergashev J. D. et al. Gamma Knife Radiosurgery for Vestibular Schwannomas: Favorable and Unfavorable Effects in Series of 42 Patients. – 2019.
9. Ganiev A. A. et al. The practice of oropharynx cancer: A case report and literature review //Annals of Cancer Research and Therapy. – 2019. – Т. 27. – №. 2. – С. 37-41.
10. Iriskulova E. et al. Intraparotid facial nerve schwannoma: a cross-country report of two cases and literature review //Annals of Cancer Research and Therapy. – 2020. – Т. 28. – №. 2. – С. 93-96.
11. Iriskulova E., Kodirova Z., Juraboev S. Prognosis of Complications at Surgical Treatment of Benign Parotid Tumors //Embedded Selforganising Systems. – 2022. – Т. 9. – №. 3. – С. 70-72.
12. Iriskulova E. et al. Intraparotid facial nerve schwannoma: a cross-country report of two cases and literature review //Annals of Cancer Research and Therapy. – 2020. – Т. 28. – №. 2. – С. 93-96.
13. Iriskulova E., Nurxojaeva A. Express assessment of sonoelastographic parameters in patients with tumors of the parotid salivary gland //Embedded Selforganising Systems. – 2022. – Т. 9. – №. 3. – С. 18-19.
14. Ismatova K. A. et al. The new coronavirus infection in otolaryngological practice: clinical features in different age groups //Science and innovation. – 2023. – Т. 2. – №. Special Issue 8. – С. 813-816.
15. Khamraeva V. S., Karabaev H. E., Ergashev J. D. The choice of optimal medical method for exudative otitis media in children //CHOICE. – 2018. – Т. 4. – С. 24-2018.
16. Shovkatovich S. O., Muratovna N. M. OPTIMIZATION OF COMPLEX THERAPY FOR CHRONIC RECURRENT APHTHOUS STOMATITIS //World Scientific Research Journal. – 2025. – Т. 45. – №. 1. – С. 119-123.
17. Shovkatov O.Sh., Sharipov S.S., Akhundjanov R.A. / 2025. MODERN PROSTHODONTIC TECHNOLOGIES IN COMPLETE EDENTULISM: APPLICATION OF CAD/CAM AND 3D PRINTING. *Журнал гуманитарных и естественных наук*. 2, 28 [2] (дек. 2025), 6–13.
18. Shovkatov O.Sh., Sharipov S.S., Akhundjanov R.A. 2025. BIOMATERIALS AND THEIR BIOLOGICAL COMPATIBILITY: A CLINICAL ANALYSIS OF PMMA, THERMOPLASTICS, BIOACTIVE POLYMERS, NANOMATERIALS, AND NEXT-GENERATION ZIRCONIA. *Журнал гуманитарных и естественных наук*. 2, 28 [2] (дек. 2025), 19–25.
19. Shovkatov O.Sh., Mirsaidov M.M. (2026). KATTA CHAYNOV TISHLARI EKSTRAKSIYASIDAN KEYINGI YALLIG‘LANISHLARNING OLDINI OLISHDA ANTIBIOTIKLAR SAMARADORLIGINI VAHOLASH. *ОСНОВЫ МЕДИЦИНЫ*, 1(8), 147–150. извлечено от <https://journals.tnmu.uz/tas/article/view/3760>
20. Yun J. M. et al. Optimizing Cochlear Implant Position for Magnetic Resonance Imaging of Vestibular Schwannoma //Laryngoscope Investigative Otolaryngology. – 2025. – Т. 10. – №. 6. – С. e70319.

